Climb Bio, Inc. (CLYM)
NASDAQ:CLYM
Want to see CLYM full AI Analyst Report?
Top Page
Climb Bio
(NASDAQ:CLYM)
Select Model
Select Model
Rating:55Neutral
Price Target:
$11.50
▲(25.55% Upside)
Action:Reiterated
Date:06/13/26
The score is held back most by weak financial performance (pre-revenue, sustained losses and high cash burn), partially offset by strong technical trend signals and generally positive clinical/pipeline updates. Valuation offers limited support given the negative P/E and no dividend, while recent financing improves liquidity but adds dilution risk.
Positive Factors
Low Financial Leverage
Minimal debt materially lowers solvency and interest burdens for a pre-revenue biotech, preserving flexibility to fund multi-year clinical programs. Low leverage reduces bankruptcy risk and gives management latitude to prioritize R&D investment and strategic partnering without fixed creditor constraints.
Negative Factors
Pre-Revenue with High Cash Burn
Sustained negative operating and free cash flows create ongoing funding dependence and heighten execution risk for multi-year trials. Elevated cash burn forces frequent capital raises, which can delay development timelines if financing conditions tighten and increases the probability of program slowdowns or prioritization choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Minimal debt materially lowers solvency and interest burdens for a pre-revenue biotech, preserving flexibility to fund multi-year clinical programs. Low leverage reduces bankruptcy risk and gives management latitude to prioritize R&D investment and strategic partnering without fixed creditor constraints.
Read all positive factors
Climb Bio (CLYM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$655.09M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth67.20%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding57,263,023
10 Day Avg. Volume1,586,881
30 Day Avg. Volume1,094,915
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.98K
Enterprise Value/Ebitda-14.04
Forecast
1Y Price Target
$22.00Price Target Upside140.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Climb Bio Business Overview & Revenue Model
Company Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is ...
How the Company Makes Money
null...
Climb Bio Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -106.00K | -97.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -52.66M | -59.75M | -30.36M | -35.12M | -45.24M | -47.48M |
| Net Income | -52.79M | -59.85M | -73.90M | -35.12M | -45.24M | -47.48M |
Balance Sheet | ||||||
| Total Assets | 152.37M | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M |
| Cash, Cash Equivalents and Short-Term Investments | 109.56M | 101.08M | 150.92M | 106.80M | 123.57M | 136.48M |
| Total Debt | 479.00K | 541.00K | 532.00K | 349.00K | 480.00K | 0.00 |
| Total Liabilities | 4.29M | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M |
| Stockholders Equity | 148.09M | 160.47M | 211.88M | 107.60M | 128.72M | 167.20M |
Cash Flow | ||||||
| Free Cash Flow | -53.49M | -54.54M | -15.56M | -20.60M | -37.37M | -36.07M |
| Operating Cash Flow | -53.30M | -54.36M | -15.56M | -20.60M | -37.37M | -36.07M |
| Investing Cash Flow | 32.63M | 2.83M | -121.09M | 68.98M | 34.44M | -114.97M |
| Financing Cash Flow | -16.00K | -21.00K | 130.73M | 841.00K | 0.00 | 177.23M |
Climb Bio Technical Analysis
Positive
9.16
Price Trends
9.98
Positive
8.08
Positive
5.33
Positive
Market Momentum
0.27
Positive
56.63
Neutral
47.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Positive. The current price of 9.16 is below the 20-day moving average (MA) of 10.92, below the 50-day MA of 9.98, and above the 200-day MA of 5.33, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 56.63 is Neutral, neither overbought nor oversold. The STOCH value of 47.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLYM.
Climb Bio Risk Analysis
Climb Bio disclosed 71 risk factors in its most recent earnings report. Climb Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Climb Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $655.09M | -14.78 | -31.46% | ― | ― | 67.20% | |
54 Neutral | $108.29M | -5.51 | -72.68% | ― | ― | 64.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $147.74M | -4.50 | -153.99% | ― | ― | 94.79% | |
50 Neutral | $43.84M | -1.71 | 241.39% | ― | ― | 38.95% | |
48 Neutral | $137.42M | 1.94 | -23.05% | ― | 24.46% | ― | |
48 Neutral | $429.27M | -7.02 | -22.51% | ― | 1199.64% | 30.81% |
* Healthcare Sector Average
CLYM
Climb Bio
11.44
10.17
800.79%
AGEN
Agenus
3.30
-1.84
-35.80%
HURA
TuHURA Biosciences
2.32
-0.25
-9.73%
OVID
Ovid Therapeutics
2.30
2.01
693.10%
CGTX
Cognition Therapeutics
1.21
0.89
278.12%
TVGN
Tevogen Bio Holdings
10.47
-53.03
-83.51%
Climb Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Climb Bio Establishes New At-the-Market Equity Program
Positive
Jun 12, 2026
On June 12, 2026, Climb Bio, Inc. entered into a new Open Market Sale Agreement with Jefferies LLC allowing the company to sell up to $100 million of its common stock from time to time in an at‑the‑market offering under an effective sh...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Reports Encouraging Early Budoprutug ITP Data
Positive
Jun 11, 2026
On June 11, 2026, Climb Bio, Inc. reported initial data from the ongoing Phase 1b portion of its Phase 1b/2a trial of budoprutug in adults with primary immune thrombocytopenia, covering 15 heavily pretreated patients in 250 mg and 500 mg intraveno...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors
Positive
Jun 8, 2026
At Climb Bio’s 2026 Annual Meeting of Stockholders held on June 5, 2026, shareholders approved an amendment to the 2021 Equity Incentive Plan to include prefunded warrants when calculating the automatic annual increase to the plan’s sh...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Reports Positive Early-Stage Data for CLYM116
Positive
Jun 5, 2026
On June 5, 2026, Climb Bio reported translational pharmacometric modeling and initial Phase 1 safety results for CLYM116, showing that pooled non-human primate data can project human exposure and dose-dependent IgA suppression, potentially enablin...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Highlights Budoprutug Progress at R&D Spotlight
Positive
May 5, 2026
On May 5, 2026, Climb Bio held a virtual RD Spotlight investor event to showcase progress on budoprutug, its clinical-stage anti-CD19 monoclonal antibody for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus....
Business Operations and StrategyPrivate Placements and Financing
Climb Bio Raises $110 Million in Private Placement
Positive
Apr 28, 2026
On April 27, 2026, Climb Bio, Inc. entered into a securities purchase agreement with a group of institutional accredited investors, including an affiliate of RA Capital Management, to raise approximately $110 million through a private placement of...
Business Operations and StrategyExecutive/Board Changes
Climb Bio Consolidates Financial Leadership After SVP Departure
Neutral
Apr 3, 2026
On April 1, 2026, Climb Bio, Inc. and Senior Vice President, Finance and principal accounting officer Cindy Driscoll mutually agreed that she would depart the company, with her separation taking effect on April 30, 2026. In connection with her dep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.